V
Vanitha Sekar
Researcher at Tibotec
Publications - 31
Citations - 1593
Vanitha Sekar is an academic researcher from Tibotec. The author has contributed to research in topics: Darunavir & Ritonavir. The author has an hindex of 21, co-authored 31 publications receiving 1558 citations.
Papers
More filters
Journal ArticleDOI
Darunavir: pharmacokinetics and drug interactions.
TL;DR: Reports from resource-limited countries suggest that initial ART programmes are as effective as in resource-rich countries, which should limit HIV drug resistance if programme effectiveness continues during scale-up.
Journal ArticleDOI
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Anthony M. Mills,Mark T. Nelson,Dushyantha Jayaweera,Kiat Ruxrungtham,Isabel Cassetti,Pierre Marie Girard,Cassy Workman,Inge Dierynck,Vanitha Sekar,Carline Vanden Abeele,Ludo Lavreys +10 more
TL;DR: Once-daily darunavir/ritonavir was both statistically noninferior and superior in virologic response to LPV/r, with a more favorable gastrointestinal and lipid profile, confirming DRV/ r as an effective, well tolerated, and durable option for antiretroviral-naive patients.
Journal ArticleDOI
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study
Christophe Moreno,Thomas Berg,Tawesak Tanwandee,Satawat Thongsawat,Hans Van Vlierberghe,Stefan Zeuzem,Oliver Lenz,Monika Peeters,Vanitha Sekar,Goedele De Smedt +9 more
TL;DR: The results of this phase IIa proof-of-concept trial provide evidence that TMC435 has a spectrum of activity against multiple HCV genotypes, except for genotype 3.
Journal ArticleDOI
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers.
Monika Schöller-Gyüre,Thomas N. Kakuda,Vanitha Sekar,Brian Woodfall,Goedele De Smedt,Eric Lefebvre,Monika Peeters,Richard M. W. Hoetelmans +7 more
TL;DR: No clinically relevant changes in DRV pharmacokinetics were observed when combined with TMC125; therefore DRV dose adjustment is not required; therefore TMC 125 efficacy is demonstrated and no dose adjustment of T MC125 is needed when Combined with DRV/r.
Journal ArticleDOI
The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.
Vanitha Sekar,Dries Kestens,Sabrina Spinosa-Guzman,Martine De Pauw,Els De Paepe,Tony Vangeneugden,Eric Lefebvre,Richard M. W. Hoetelmans +7 more
TL;DR: Darunavir/rtv should be administered with food, but exposure to darunavIR is not affected by the type of meal, as no significant differences in dar unavir plasma concentrations were observed between different fed states.